422 results about "IV Chemotherapy" patented technology

The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

The invention discloses a pharmaceutical composition for reversing pancreatic cancer gemcitabine drug resistance and application of the pharmaceutical composition, and belongs to the technical field of biological medicine. The composition comprises a generic FGFR inhibitor delatinib and gemcitabine, the concentration of the delatinib is 25 to 50 mg / kg, and the concentration of the gemcitabine is 20 to 30 mg / kg. By inhibiting an FGFR2 / FGFR3 signal channel and reducing the expression of FGFR protein in drug-resistant cells, the chemosensitivity of gemcitabine is synergistically enhanced, the apoptosis induction rate is increased by more than two times, and the synergic index (CI) is less than 1. In-vitro and nude mouse transplantation tumor experiments prove that the composition can significantly inhibit the proliferation of gemcitabine drug-resistant pancreatic cancer cells. The Gemcitabine drug-resistant pancreatic cancer drug can be used for preparing a drug for treating Gemcitabine drug-resistant pancreatic cancer with high FGFR3 expression, patients are screened through immunohistochemistry or gene sequencing, intravenous injection or oral administration is adopted, dosage forms comprise freeze-dried powder injection, capsules or tablets, and a new strategy is provided for pancreatic cancer drug-resistant treatment.

The invention relates to the technical field of tumor biomedical engineering and organ chips, in particular to a vascularized gastric cancer organ chip and a preparation method thereof.The chip is composed of an integrated micro-fluidic main body, an annular micro-column array and an optical sealing film, and a central culture cavity is divided into a tumor area and a blood vessel area by micro-columns; the preparation method comprises the following steps: injecting a fibrous protein solution containing human umbilical vein endothelial cells and cancer-related fibroblasts into a vascular region, and adding thrombin for in-situ gelation to form a pre-vascularized network; the method comprises the following steps: mixing a patient-derived gastric cancer organ with a methacrylic acid esterified gelatin pre-polymerized solution, injecting the mixture into a tumor area, and carrying out photo-crosslinking immobilization; culturing for 7-14 days under the dynamic perfusion condition of a mixed culture medium to obtain a three-dimensional gastric cancer organ model containing a capillary network; the method is expected to be used for rapid, low-cost and high-throughput screening of chemotherapy or anti-angiogenesis drugs and accurate prediction of individual curative effects of patients.

A hybrid liver cancer prognosis model, prognosis system and medium, the model takes independent influence factors as input and outputs hybrid liver cancer postoperative risk scores, the hybrid liver cancer postoperative risk scores are used for dividing risk levels, and the risk levels are used for hybrid liver cancer prognosis evaluation. And / or is used for postoperative adjuvant chemotherapy decision-making of mixed liver cancer. The hybrid liver cancer prognosis model is jointly constructed by combining the traditional clinical pathological characteristics and immune microenvironment indexes, the key effect of the tumor immune microenvironment in CHC prognosis is indicated, and the constructed hybrid liver cancer prognosis model has good CHC prognosis prediction performance; in addition, decisions of postoperative adjuvant chemotherapy can be provided for patients with different risk levels, precise treatment of the CHC patients is achieved, and long-term survival prognosis of the CHC patients is improved.

The invention discloses a gastric cancer postoperative chemotherapy dynamic intervention method and system based on time point matching, and relates to the technical field of postoperative intervention. Health state data of wearable medical equipment of a gastric cancer postoperative patient is collected; preliminarily dividing the stomach cancer postoperative chemotherapy cycle into a plurality of key physiological time points based on the symptom inflection points, and respectively matching an intervention core problem and a corresponding stomach cancer postoperative chemotherapy intervention scheme for the plurality of key physiological time points; and the postoperative intervention platform analyzes the time period health state data collected by the wearable medical equipment at set time intervals, analyzes the health state data to automatically identify gastric cancer postoperative symptom inflection points, and dynamically matches key physiological time points based on symptom inflection point results. The stomach cancer postoperative treatment disruption rate is reduced, the crisis inflection point recognition accuracy is greatly improved, and the bone marrow suppression early diagnosis rate is greatly improved; the early diagnosis rate of postoperative wound infection of gastric cancer is improved, unnecessary intervention is reduced, and crisis event treatment is accelerated.

The invention belongs to the technical field of medicines, and particularly relates to a preparation method of a scrophularia ningpoensis extract for relieving chemotherapy-induced acute kidney injury and application of the scrophularia ningpoensis extract in preparation of a product for relieving chemotherapy-induced acute kidney injury. The preparation method comprises the following steps: putting fresh ginseng into a high-temperature and high-pressure sterilization pot, steaming at 110-120 DEG C for 1-3 hours, taking out, cooling to room temperature, and repeating the steaming cooling process for 2-5 times; and crushing the treated ginseng materials, adding a mixed strain of saccharomyces cerevisiae and lactobacillus plantarum in a mass ratio of 1: 1, fermenting for 24-72 hours, filtering fermentation liquor, and drying filter residues to obtain the black ginseng extract. The cisplatin-induced acute kidney injury is prevented and / or treated by improving oxidative stress and mitochondrial functional activity, reducing the content of lipid peroxide, inhibiting expression of inflammatory factors TNF alpha, IL1beta and COX2 and remarkably reducing the cell apoptosis rate and the level of inflammatory factors related to endoplasmic reticulum stress.

The invention relates to a breast cancer chemotherapy myocardial stress quantitative evaluation method, which comprises the following steps of: acquiring an electromechanical response signal of a myocardial tissue of a chemotherapy patient in a pulsation period, extracting an electromechanical coupling delay parameter of a local tissue, and identifying an initial region of a chemotherapy-induced myocardial stress reaction; for the identified stress starting region and the adjacent cardiac muscle tissue, acquiring the transcellular membrane response time difference, and calculating a stress conduction lag difference index for characterizing the chemotherapy-induced asymmetric stress conduction characteristic; controllable micro-load intervention is carried out on a patient, and a strain reaction curve of a stress starting area and peripheral tissues after the load is applied is monitored; based on the response lag time, the strain peak change rate and the dynamic trend of recovering to the baseline in the load response process, the stress response elastic coefficient of the myocardial tissue is obtained through inversion and is used for quantifying the stress level of the myocardial after breast cancer chemotherapy; tiny changes of myocardial functions are quantified, and a trend judgment basis is provided.

The invention provides a multifunctional intelligent anti-thrombus PICC (peripherally inserted central catheter) for tumor chemotherapy, which comprises a catheter body, a catheter tip, a main infusion cavity, a first auxiliary cavity and a second auxiliary cavity, and the first auxiliary cavity and the second auxiliary cavity are arranged around the main infusion cavity to form a spiral structure; a micro pressure sensor array is embedded in the pipe wall of the first auxiliary cavity; a biological impedance measuring electrode pair is embedded in the pipe wall of the second auxiliary cavity; and the micro pressure sensor array, the biological impedance measuring electrode pair, the micro ultrasonic transducer and the temperature sensor are connected with a processor. According to the method, active thrombus prevention is achieved, passive treatment is changed into active prevention through a triple mechanism, and the thrombus occurrence rate is greatly reduced; meanwhile, the tube body is formed by mutually winding, fusing and extruding three independent cavities (a main infusion cavity, a first auxiliary cavity and a second auxiliary cavity) like a DNA double helix (triple helix is provided herein); and the mechanical stimulation and damage to the inner wall of the blood vessel are reduced.

Disclosed herein are methods of treating an individual having a gastroesophageal cancer, of treating or identifying an individual having gastroesophageal cancer for a treatment, or stratifying individuals having a gastroesophageal cancer for a treatment based on a tumor mutational burden (TMB) score or a TMB score.

The invention discloses a culture system, culture method and application of gastrointestinal tumor chemotherapy drug-resistant organoid, the culture system comprises: a basic culture medium, which is a DMEM / F12 culture medium, and is additionally added with a special growth promoting factor obtained from a natural extract; the multiple growth factors comprise an epidermal growth factor (EGF), a fibroblast growth factor (FGF), a bone morphogenetic protein (BMP) and a vascular endothelial growth factor receptor inhibitor (VEGFRi), and the concentration of each growth factor is accurately screened and optimized; the extracellular matrix is Matrigel modified by physical and chemical methods; the specific additive comprises an antioxidant N-acetylcysteine (NAC). According to the culture system, the culture method and the application of the gastrointestinal tumor chemotherapy drug-resistant organoid, the culture system which is closer to a real environment in vivo is constructed by optimizing basic culture medium components, setting various growth factors and specific additive concentrations and adopting modified Matrigel as an extracellular matrix.

The invention relates to the technical field of gastrointestinal tumor chemotherapy risk assessment, and particularly discloses a gastrointestinal tumor chemotherapy risk scoring model and a construction method thereof, and the method comprises the steps: obtaining the individualized feature data and basic physiological data of a historical patient, and constructing an individualized difference library with a unique ID, and a core influence library; the method comprises the following steps: standardizing and coding double-library data, synchronizing clinical data containing treatment effect codes, forming a data dictionary, acquiring and coding current gastrointestinal tumor patient data, and matching the data dictionary to judge individual difference abnormity; when the first data set is abnormal, constructing a first data set, screening core independent variables through Logistic regression, and constructing a scoring model by using an LSTM (Long Short Term Memory) model; when no abnormity exists, redundant codes are removed to obtain a second data set, and modeling is conducted through the same method. Through double-library linkage and scene-divided modeling, the three-level toxicity risk prediction precision is improved, data support is provided for clinical chemotherapy dose adjustment and toxicity prevention, and the risk of excessive treatment or insufficient treatment is reduced.

The invention provides a solid-liquid phase-change microcapsule cooling cold cap for preventing alopecia in chemotherapy. The solid-liquid phase-change microcapsule cooling cold cap comprises a shell layer, a phase-change cooling layer and a heat-conducting attaching layer, the phase change cooling layer is sealed between the heat conduction bonding layer and the shell layer; the phase change cooling layer comprises a frame and phase change microcapsules; the frame is built between the shell layer and the heat-conducting laminating layer, and the phase change microcapsules are filled between the shell layer and the heat-conducting laminating layer; the phase change microcapsule is a microcapsule encapsulated by a low-temperature solid-liquid phase change material; the solid-liquid phase change material is used as a cooling material, the cooling effect is remarkable, the solid-liquid phase change material is not particularly hard after being frozen, still has a certain deformation space and can be attached to all parts of the head of a patient, medical silica gel is used as the scalp attaching layer, the scalp attaching layer is soft, breathable and good in heat conduction and scalp attaching effect, and the cooling effect is good. The cold cap and the head of the patient are attached more tightly, and the phenomenon that a gap exists between the cold cap and the scalp, and the head anti-falling effect is affected after chemotherapy is avoided.

The utility model belongs to the technical field of medical equipment, and discloses a vomiting relieving treatment device for tumor chemotherapy, which comprises a massage module, a fastening mechanism is arranged on the outer wall of the massage module, and a rolling mechanism is arranged on the outer wall of the massage module; the winding mechanism comprises a winding drum, a partition plate is fixedly connected to the inner wall of the winding drum, a rotating shaft is elastically connected to the outer wall of the partition plate through a volute spiral spring, a clamping groove is formed in the outer wall of the rotating shaft, a fixing block is fixedly connected to the outer wall of the front end of the winding drum, and a limiting block is elastically connected to the inner wall of the fixing block through a connecting spring. The pull-out length of the bandage can be fixed through clamping connection of the limiting block and the clamping groove, limiting of the rotating shaft is removed when the bandage is not used, the bandage can be automatically wound in the winding barrel, space is saved, and the problems that the bandage is wound disorderly due to the fact that the bandage is exposed all the time, and the bandage is inconvenient to tidy in the using process are solved.

Provided herein are compositions and methods for treating a relapsed or refractory hematologic cancer in a human patient in need thereof. The methods entail administering to the patient a daily dose of about 10 mg to about 75 mg of cerdulatinib or a pharmaceutically acceptable salt thereof, wherein the patients suffer one or more of a B-cell malignancy, chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) or other transformed FL and / or have relapsed or not responded to a prior chemotherapy.

According to the breast cancer prediction model construction system based on the MRI image and the storage medium provided by the invention, the model for predicting the neoadjuvant chemotherapy pathological alleviation condition and prognosis of the breast cancer patient is constructed by combining the dynamic change of the blood vessel characteristics and the clinical pathological characteristics, so that the system has relatively high accuracy and clinical practicability, and is suitable for popularization and application. And making of an individualized adjuvant therapy scheme is facilitated. The method can early predict breast pathology remission and long-term prognosis, and can early and accurately predict neoadjuvant chemotherapy curative effect and long-term prognosis of breast cancer patients. The model predicts whether a patient can achieve complete relieving of breast pathology or not by analyzing changes of breast tumor blood vessel characteristics in the chemotherapy process and correlation with clinical factors, and further predicts the recurrence-free lifetime of the patient, so that a reference basis is provided for individualized treatment.

The utility model relates to an abdominal cavity hyperthermic perfusion chemotherapy device which comprises an abdominal pressure belt and a perfusion assembly, and the perfusion assembly comprises a drainage tube which penetrates through the abdominal pressure belt and is detachably connected with the abdominal pressure belt; a partition plate is arranged in the drainage tube along the longitudinal axis, the partition plate can divide an inner tube cavity of the drainage tube into an independent perfusion cavity and an independent extraction cavity, a plurality of ribs extending in the length direction of the drainage tube are arranged on the inner tube wall of the perfusion cavity and the inner tube wall of the extraction cavity, and the ribs form a first blank section in the perfusion cavity in a vacancy reserving mode. A second blank section is formed in the extraction cavity, a first baffle and a second baffle which can be opened and closed are arranged at the far end of the partition plate, and when the two baffles are closed, the first baffle can be limited in the first blank section so as to block an outlet of the perfusion cavity; and the second baffle can be limited in the second blank section to block the outlet of the extraction cavity.

The invention discloses application of circFAM126A in preparation of a medicine for reversing oxaliplatin resistance of gastric cancer, and belongs to the technical field of molecular biology. According to the application disclosed by the invention, by constructing a lentivirus for targeted interference of novel circFAM126A and transfecting gastric cancer cells, it is proved that the lentivirus carrying a specific interference sequence can stably knock down circFAM126A expression in the gastric cancer cells, the drug resistance of the gastric cancer cells to oxaliplatin is effectively reversed, the tumor cell death effect induced by chemotherapeutic drugs is remarkably enhanced, and the tumor cell death effect is remarkably improved. Meanwhile, the proliferation and clone formation capability of gastric cancer cells is inhibited. Meanwhile, it is found that circFAM126A is highly expressed in oxaliplatin-resistant gastric cancer cells and is in positive correlation with poor prognosis of gastric cancer patients, a detection reagent aiming at circFAM126A can be used for auxiliary diagnosis of gastric cancer prognosis conditions, and the drug resistance degree of the gastric cancer cells to oxaliplatin can be evaluated by detecting the expression level of circFAM126A.

The invention discloses a platinum (IV)-pirfenidone compound prodrug, a preparation method and microenvironment remodeling anti-tumor application, and belongs to the field of medical technology and drug synthesis. A series of molecules are characterized by being platinum prodrugs modified by pirfenidone derivatives. The synthesis method sequentially comprises the following steps: oxidizing platinum drugs, modifying hydroxyl groups, and introducing pirfenidone derivatives through esterification reaction. A series of molecules are reduced into Pt (II) drugs at the focus to kill cancer cells, and meanwhile, the released pirfenidone derivative can remodel the tumor microenvironment. The platinum prodrug disclosed by the invention not only has excellent cancer cell killing ability, but also is relatively low in drug resistance and excellent in safety, can trigger immunogenic cell death, and is a brand new chemotherapy-immunotherapy method. A series of molecules are convenient to synthesize, the preparation process is simple, and the amphipathicity is excellent, the anti-cancer capability is excellent, the drug resistance and toxicity are low, and the clinical application prospect is good.

The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer. The methods also relate to generating a drug- resistant cytotoxic immune cell line and uses thereof in conjunction with cytotoxic drugs.

The invention relates to the technical field of medical care, and discloses a chemotherapy nursing device for medical oncology, comprising: an infusion seat for infusion; the lower annular plate is arranged at the top of the infusion seat; the upper ring plate is arranged at the top of the lower ring plate; the diaphragm is arranged in the upper annular plate; the inner sealing piece is arranged on the inner side of the lower annular plate and used for connecting the lower annular plate with the inner wall of the upper annular plate; and the outer sealing piece is arranged on the outer side of the lower annular plate. Positioning of the upper annular plate by a positioning assembly is omitted, so that the position of the upper annular plate can be adjusted, the position of the diaphragm can be adjusted, the central needle inserting position of the diaphragm can avoid a disease skin area, normal needle inserting can be guaranteed, the upper annular plate is heated through a heating ring, and the needle inserting efficiency is improved. And heat is transferred to the skin, so that the skin cannot be tightened due to coldness, and the upper ring plate can be easily pushed subsequently.

The invention discloses an application of a reagent for detecting AP3S2 in preparation of a diagnostic reagent for neoadjuvant immunochemotherapy resistance of gastric cancer in a local progression stage, which comprises the following steps: screening differential expression proteins in neoadjuvant immunochemotherapy resistance tissues of gastric cancer in the local progression stage through proteomics; a new marker is provided for diagnosis of the local progression stage gastric cancer immunochemotherapy drug resistance, and a basis is also provided for development and future development of a local progression stage gastric cancer immunochemotherapy drug resistance diagnosis method.

The present application relates to the technical field of biological medicine, and discloses inhalable aptamer modified molybdenum disulfide nanoflower compound and application thereof.The compound comprises a molybdenum disulfide nanoflower core, a dendritic polylysine modification layer attached to the surface of the molybdenum disulfide nanoflower, doxorubicin loaded on the molybdenum disulfide nanoflower and / or the dendritic polylysine modification layer, and AS1411 aptamer combined on the outer surface of the dendritic polylysine modification layer by electrostatic assembly.The compound can be delivered to a lung lesion by atomization inhalation or aerosol inhalation, and undergoes responsive structural change under the action of hydrogen peroxide in a tumor microenvironment, generates active oxygen, and promotes the release of doxorubicin, so as to realize the synergistic antitumor effect of chemotherapy and chemical dynamic therapy.The compound has good colloidal stability, drug loading capacity, active targeting ability and lung local delivery potential, and can be used for preparing inhalation preparations or local administration preparations for treating lung cancer.

This invention discloses a hydrogel for tumor treatment based on improving the tumor microenvironment to trigger gas therapy combined with chemotherapy, belonging to the field of biomedical technology. The hydrogel drug delivery system utilizes lipopolysaccharide (LPS) to induce local inflammatory stimulation, thereby altering the tumor microenvironment of breast cancer and promoting nitric oxide (NO) production. The NO donor arginine (L-Arg) and the chemotherapy drug doxorubicin (DOX) are transported using sodium alginate (ALG), achieving combined gas therapy and chemotherapy to inhibit breast tumor growth. The drug delivery system of this invention not only enhances the effect of chemotherapy but also simultaneously achieves precise drug delivery and reduces drug dosage. The preparation method of the drug delivery system of this invention is simple, safe, and without toxic side effects, showing promising application prospects in tumor treatment and possessing significant clinical value.

The present invention provides the use of plasma small extracellular vesicle miRNA markers in the preparation of a product for predicting the efficacy of combined immunotherapy and chemotherapy for lung cancer. The plasma small extracellular vesicle miRNA markers include: any one of miR-96-5p, miR-99b-3p, miR-100-5p, miR-193a-5p, miR-320d or miR-6815-5p, or a combination of at least two. The present invention models multiple sEVs miRNA combinations and identifies effective models containing two or three sEV miRNAs to determine the true responding population, showing high performance with an AUC greater than 0.9, achieving the potential benefit population for combined immunotherapy and chemotherapy of lung adenocarcinoma screened from the level of peripheral blood small extracellular vesicles.

The invention relates to the technical field of tumor chemotherapy, in particular to a nursing device used after tumor chemotherapy. According to the technical scheme, the nursing frame comprises a nursing frame body, a fixing frame and a supporting frame, the lower surface of the nursing frame body is connected with a sleeve frame, the upper surface of the nursing frame body is sleeved with the fixing frame, a fixing rod is fixed to the outer end face of one side of the fixing frame, and the outer end face of one side of the fixing rod is rotationally connected with a connecting bearing; a movable frame is rotationally connected to the outer end face of one side of the connecting bearing, a rotating plate is connected to the outer end face of one side of the movable frame, a mounting frame is connected to the lower surface of the supporting frame, a connecting frame sleeves the upper surface of the supporting frame, and a movable bearing is fixed to the outer end face of one side of the connecting frame; a rotating frame is rotationally connected to the outer end face of one side of the movable bearing, and massage layers are fixed to the inner walls of the nursing frame body, the sleeve frame, the supporting frame and the mounting frame. According to the invention, varicosity of a patient can be prevented, and liquid medicine exosmosis and phlebitis incidence rate can be reduced.

The invention relates to the technical field of adjuvant chemotherapy, and discloses a breast cancer adjuvant chemotherapy device which comprises a supporting mechanism, the supporting mechanism comprises a supporting frame, supporting legs are fixedly connected to the outer wall of the bottom of the supporting frame, and a headrest is fixedly connected to the outer wall of the top of the supporting frame. A patient needs to lie on the supporting mechanism, after the head is placed in a headrest area, a first auxiliary motor drives a rotating shaft to drive a first sliding frame to slide, then a treatment area of the chest of the patient is accurately found, and a second auxiliary motor drives a rotating wheel to slide on the inner wall of a first sliding groove; and a second telescopic rod pushes a second sliding frame to move, so that the chest chemotherapy equipment arrives at a proper position, radioactive therapy is carried out on a focus of the chest of a patient, then treatment omission can be avoided, and the risk of breast cancer recurrence is practically reduced.

The invention particularly relates to a perfusion chemotherapy dispensing device for medical oncology. A perfusion chemotherapy dispensing device for medical oncology comprises a shell and the like, a cover plate is fixedly arranged at the top of the shell, a control panel is installed on the front side of the cover plate, a plurality of containing pipes are fixedly connected to the front side of the cover plate at intervals, medicament bottles are placed in the containing pipes, and a storage assembly used for refrigerating and storing medicaments is arranged at the top of a bottom panel of the shell. The storage assembly and the side wall of the shell are jointly provided with a negative pressure suction assembly, and the negative pressure suction assembly is used for sucking the medicament in the medicament bottle into the storage assembly under the closed condition. According to the device, automatic medicament extraction is achieved, manual extraction is avoided, medicament exposure is reduced, the occupational exposure risk of medical staff is reduced, quantitative injection and stirring mixing are achieved, accurate and efficient dispensing is guaranteed, medicaments can be stored in a pre-filling mode, use is convenient and rapid, the stirring barrel can be cleaned, different medicaments can be prepared conveniently, and medicament waste and efficacy loss are reduced.

The application discloses a medical hollow tube positioning and marking device and belongs to the technical field of breast tumor marking. The device comprises a head, a fixing ring, an inner core, a hollow flexible tube and a needle cylinder. The fixing ring is fixed at intervals on the hollow flexible tube to form a long chain. The head is fixed at the head end of the long chain to form a marking body. The inner core penetrates into the hollow flexible tube to the head end to push the marking body to move in the needle cylinder. The front end of the needle cylinder is provided with a needle part. After puncture, the needle cylinder and the inner core are used to push the head outward and the marking body is pushed out and positioned. The marking body exposed outside is cut off. Multi-directional marking is used to form stereoscopic, linear and visual positioning. The marking body can be freely bent and is not easy to be cut off and displaced. The risk of infection or accidental injury caused by a traditional positioning steel wire is reduced. Breast cancer patients receiving neoadjuvant chemotherapy only need to be positioned and marked once and do not need to bear the secondary trauma of steel wire positioning again after traditional marking clamp marking.

The present disclosure relates to 1-(2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)acetyl)-4- hydroxypyrrolidine-2-carboxamide derivatives and structurally related compounds of formula (I) as VHL inhibitors for the treatment of e.g. anemia (e.g. chronic anemia or anemia associated with chronic kidney disease, dialysis or cancer chemotherapy), ischemia, stroke or injury to the cardiovascular system during ischemia, or for enhancing wound healing, reducing scarring or enhancing angiogenesis or arteriogenesis.